Atrium Therapeutics Stock Climbs: The Key FDA Filing Investors Are Watching Now
Atrium Therapeutics shares rose 1.9% to $12.96 in Thursday afternoon trading, giving the San Diego-based ribonucleic acid drug developer a market value of about $222 million. The Nasdaq-listed stock traded between $12.62 and $13.07, with volume at 152,813 shares in the latest available market data. The move matters now because Atrium is still being priced more on cash, platform promise and upcoming regulatory steps than on clinical results. Its first big near-term marker is an Investigational New Drug application, or IND — a request to regulators to begin human testing — for ATR 1072, which the company expects to submit in the second half of 2026.